

+

+

App. for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/521922
				Filing Date	20 January 2005
				First Named Inventor	PAPIEROK, Gerard et al
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	1811-61
Sheet	1	of	2		

[illegible][illegible]


Examiner Signature	/Brian Gangle/	Date Considered	09/06/2006
-----------------------	----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

+

Please type a plus sign (+) inside 

PTO/SB/08B (10-96)  
 App. for use through 10/31/99. OMB 0651-0031  
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE          STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/521922
				Filing Date	20 January 2005
				First Named Inventor	PAPIEROK, Gerard et al
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	1811-61

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
BG		DEPLAZES, P. et al, "Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites." PARASITE IMMUNOLOGY ( England ), vol. 17, no. 9, September 1995, pp. 451-458.		
BG		JIMENEZ-RUIZ, A. et al, "Cloning, sequencing, and expression of the PSA genes from Leishmania infantum." EUROPEAN JOURNAL OF BIOCHEMISTRY (Germany), vol. 251, no. 1-2, 15 January 1998, pp. 389-397.		
BG		KEMP, M. et al, "The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognized by Th1 cells in humans with naturally acquired immunity to L. major." FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY (Netherlands), vol. 20, no. 3, March 1998, pp. 209-218.		
BG		CIBRELUS, P. et al, "Secreted antigens of the amastigote and promastigote forms of Leishmania infantum inducing a humoral response in humans and dogs." PARASITE (France), vol. 6, no. 2, June 1999, pp. 121-129.		
BG		RIERA, C. et al, "Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate" VETERINARY PARASITOLOGY (Netherlands), vol. 84, no. 1-2, July 1999, pp. 33-47.		

Examiner Signature	/Brian Gangle/	Date Considered	09/06/2006
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.